An extremely rare mucocutaneous adverse reaction following COVID ‐19 vaccination: Toxic epidermal necrolysis

Abstract

Stevens‐Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), is a type of delayed hypersensitivity reaction that requires urgent medical intervention. In the COVID‐19 era, COVID‐19 vaccines are currently being widely administered and mucocutaneous adverse reactions following vaccination have been reported; however, severe cutaneous adverse reactions associated with COVID‐19 vaccines including SJS/TEN, are extremely rare. Herein, we describe a case of COVID‐19 vaccination induced TEN which developed 1 day after receiving the first dose of Sinopharm COVID‐19 vaccine with favorable clinical outcome.

Erythema Multiforme as Early Manifestation of COVID-19: A Case Report

“…This syndrome occurs mostly in adults between 20 and 40 years old, with similar manifestations to those reported in our case of multiple ulcerations, erythema and bullae [15]. Moreover, SJS is extremely rare with vaccination [15,16]; this is relevant information since the patient in this case had not received any vaccination against COVID-19.…”

Management of Secondary Leyll Syndrome Due to Anti-Covid Vaccine in a Case, at the Renaissance University Teaching Hospital, Ndjamena (CHAD)

“…Indeed, to our knowledge, this is the first case reported in Chad during the anti-COVID-19 vaccination campaign with the Jhonson and Jhonson vaccine. Cases of Toxidermia linked to vaccines have been reported by certain observations, in particular linked to: Pzifer, Moderna, Sinopharm, as is the case with the following authors: Elboraey et al [12] in Egypt, Mardani et al [13] in Iran and Dash et al [14] in India. As we note, all the different types of COVID-19 vaccines can be responsible for this syndrome.…”

Toxic epidermal necrolysis after first dose of Pfizer‐BioNTech (BNT162b2) vaccination with pharmacogenomic testing

“…In addition, cases of SJS/TEN associated with the COVID-19 vaccine have been rarely reported and are summarized in Table 1. [4][5][6][7][8][9][10][11][12] There have been only nine reported cases of SJS/TEN after COVID-19 vaccine. Five of these patients had underlying diseases, such as hyperlipidemia, diabetes mellitus and breast cancer with a history of medication use.…”

“…In addition, cases of SJS/TEN associated with the COVID‐19 vaccine have been rarely reported and are summarized in Table 1 . 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 …”

“…Five of these patients had underlying diseases, such as hyperlipidemia, diabetes mellitus and breast cancer with a history of medication use. 6 , 7 , 8 , 11 , 12 Most cases of SJS/TEN occurred following the first dose of COVID‐19 vaccine. The onset of SJS/TEN after vaccination was about 1–2 weeks (1–14 days).…”